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UNIT 4.1A Brief History, Status, and Perspective of
Modified Oligonucleotides for
Chemotherapeutic Applications
Modification of oligonucleotides for drug
applications has a very short history (for high-
lights see Table 4.1.1 and Table 4.1.2). Inten-
sive efforts to modify short strands of nucleic
acids to enhance their properties as drug can-
didates began in earnest in the late 1980s. The
notion that oligonucleotides could be made into
drugs along with the discovery and develop-
ment of two essential enabling technologies—
automated DNA sequencing (Connell et al.,
1987) and commercial automated oligonu-
cleotide synthesis and purification in the early
1980s—set the stage for oligonucleotide drug
discovery (reviewed by Zon, 1993). Sub-
sequently, oligonucleotide medicinal chemis-
try and pharmacology, which form the basis of
structure-activity relationship studies, have
been highly developed in the process of con-
verting oligonucleotides into drugs. Before
this, little value was given to synthetically
changing the structure of short strands of DNA
or RNA except for some early modifications
primarily directed to enhance structural studies
and diagnostic applications. Now great interest
in making drugs out of oligonucleotides has
spurred intense structure-activity/property re-
lationship (SAPR) studies to optimize drug
properties (Cook, 1998a,b).
Given that oligonucleotides are gene-based
materials (or informational materials; Cohen,
1991) and considering the emergence of
genomic target selection, which is also gene-
based, it is surprising that it has taken so long
for the drug discovery community to recognize
the potential value of modified oligonu-
cleotides as drugs. However, when traditional
medicinal chemists first consider modifying
oligonucleotides, they are confronted with a
number of daunting chemical, biophysical, and
biochemical properties of oligonucleotides
(Table 4.1.3), which has surely slowed progress
in this area. In addition to the need to apply
novel ligands to drug discovery, the nucleic acid
targets that serve as receptors, particularly RNA
molecules, are novel as well. In spite of the
early difficulties in exploring the use of oli-
gonucleotides as drugs, however, much pro-
gress has been made in recent years. The first
antisense oligonucleotide drug, Vitravene, was
recently approved by the Food and Drug Ad-
ministration (FDA) for treating cytomega-
lovirus retinitis in AIDS patients, and several
additional oligonucleotides are in late phase II
and III clinical studies for anti-cancer and anti-
inflammatory indications (Table 4.1.4).
OVERVIEW OF BASE PAIRING
AND GENE EXPRESSION
A single strand of nucleic acid has a poly-
meric sugar-phosphate backbone with ribo-
furanosyl (in RNA) or deoxyribofuranosyl (in
DNA) residues connected at the 3′ and 5′ hy-
droxyls by phosphoric acid to form phosphodi-
ester linkages. Each sugar residue has one of
Table 4.1.1 Historical Listing of Oligo- and Polynucleotides as Therapeutic Agents
Milestone References
DNA alkylating agents Belikova et al. (1967); Summerton (1979)
Poly(rI) • poly(rC) De Clercq et al. (1969)
Macromolecular antimetabolites
 “Antitemplates”
Chandra and Bardos (1972); reviewed by
Bardos and Ho (1978)
Antisense oligonucleotides (targeting RNA) See Table 4.1.2
Heterocycle modified oligonucleotides:
 prodrugs for nucleosides
Alderfer et al. (1985)
Antigene oligonucleotides: triple strand
 formers
Moser and Dervan (1987); LeDoan et al.
 (1987)
Aptamers Ellington and Szostak (1990); Tuerk and Gold
 (1990)
Sense approach Morishita et al. (1995)
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five types of heterocycles (nucleobases) at-
tached at the C1′ position of either the deoxyri-
bofuranosyl or ribofuranosyl sugar. These het-
erocycles are the purines (guanine and adenine)
and the pyrimidines (cytosine and thymine,
with uracil replacing thymine in RNA).
Complementary DNA describes a chemi-
cal complex of two strands of deoxyribonu-
cleic acid that are bound together by Watson-
Crick base-pair hydrogen bonding. This “es-
sences of life” bonding specifies that guanine
in one DNA strand specifically binds to cy-
tosine in the other strand, and that adenine in
one DNA strand specifically binds to thymine
in the other strand (Fig. 4.1.1). In RNA, uracil
specifically binds to adenine. A sequence (or
a specific ordering of nucleobases) of an
RNA or a DNA strand will bind specifically
(hydrogen bond) to another sequence only if
the nucleobases match up (base pair). The
strands are then said to be complementary to
one  another.
The complementary DNA strands twist into
a helical motif with one strand having its bases
ordered in the 3′ to 5′ direction and the other
strand having its bases ordered in the opposite
direction (5′ to 3′). This is referred to as anti-
parallel orientation (Fig. 4.1.2). The double-
stranded DNA (dsDNA) serves as the template
for synthesis of either complementary DNA
molecules, to provide a process of self-replica-
tion, or complementary RNA molecules (from
the sense strand) for the process of transcrip-
tion. The complementary DNA strand, referred
to as the antisense strand, is itself rarely tran-
scribed to give an RNA molecule.
Table 4.1.2 Highlights of the Development of Chemotherapeutic Oligonucleotides
Milestone References
Antisense experiments in cell culture Stephenson and Zamecnik (1978); Zamecnik
 and Stephenson (1978)
Automated synthesis, protocols, reagents Merrifield, Letsinger, Caruthers (1962-1987)
Methylphosphonate oligonucleotides Ts’o et al. (1987)
Phosphorothioates Eckstein, Stec, Zon (1967-1981)
Ribozymes Cech (1986); Altman (1989)
Initiation of first clinical trial; first report of
 clinical efficacy
Isis Pharmaceuticals (1992-1994)
Twenty five oligonucleotides entered into
 clinical development
(1992-present; see Table 4.1.4)
First New Drug Application (NDA) for an
 antisense oligonucleotide
Isis Pharmaceuticals (April 1998)
First approved antisense oligonucleotide drug Isis Pharmaceuticals (August 1998)
Table 4.1.3 Chemical, Biochemical, and Biophysical Properties of First-Generation
Oligonucleotides
Parameter Property
Molecular weight High (20- to 25-mers, MW 7000 to 9000)
Charge Highly negative (19 to 24 charges) or neutral
Chirality in backbone P=S, Me-P, N-Pa
Instabilities Biological and chemical (nucleases, pH, depurination, dethiation)
Solubility Insoluble in common organic solvents depending on backbone
modification (P=S versus Me-P)a
Crystalline? No
Ease of synthesis Complex synthesis of reactive monomers
Unfamiliarity with instrument synthesis of oligomers
Purification by ion exchange chromatography
Analysis and characterization atypical
aMe-P, methylphosphonate; N-P, phosphoramidate; P=S, phosphorothioate.
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Table 4.1.4 Oligonucleotides Entered into Clinical Developmenta
Oligonucleotide Molecular target Diseaseindications Status
b Sponsor
ISIS 2105 HPV 6 and 11 E2
genes product
Genital warts Terminated Isis
ISIS 2922 HCMV IE gene-2 CMV retinitis NDA approved
(August 1998)
Isis/Ciba Vision
ISIS 2302 Intercellular
adhesion
molecule
(ICAM-1)
Renal allograft,
rheumatoid
arthritis, Crohn’s
disease,
ulcerative colitis,
psoriasis
III, Crohn’s;
II for others
Isis/Boehringer
Ingleheim
ISIS 3521/CPG
 64128A
Protein kinase
C-α
Cancer II Isis/Novartis
ISIS 5132/CPG
 69846A
c-raf kinase Cancer II Isis/Novartis
ISIS 13312 HCMV IE gene CMV retinitis I/II Isis
ISIS 5320 Gp120 AIDS Terminated Isis
ISIS 2503 Ha-ras Cancer I Isis
GEM-91 gag gene AIDS Terminated Hybridon
GEM-92 gag gene AIDS I Hybridon
GEM-132 UL36 and UL37 CMV retinitis I Hybridon
GEM-231 Protein kinase A Cancer II Hybridon
OL(1)p53 p53 Cancer Terminated Lynx/Inex
LR-3280 c-myc Restenosis Terminated Lynx/Inex
c-myb Cancer Terminated Lynx/Inex
GPs 0193 gag gene AIDS Terminated Chugai
Zintevir HIV integrase AIDS I/II Aronex
G3139 Bcl-2 Cancer II Genta
GPI-2A gag gene AIDS Terminated Novopharm
Biotech
GTI 2040 Ribonucleotide
reductase R2
subunit
Cancer I GeneSense
MG-98 DNA methylase Solid tumors I MethylGene
Resten-NG c-myc Restenosis and
proliferative
diseases
I AVI BioPharma
Heptazyme IRES region Hepatitis C virus I Ribozyme
Pharmaceuticals
Angiozyme Vascular
endothelial
growth factor
receptor
Anti-
angiogensis
(cancer)
I Ribozyme
CPG-x Immune system Hepatitis B I CpG
aAbbreviations: E, early gene; HCMV, human cytomegalovirus; HPV, human papillomavirus; IE, immediate early gene;
IRES, internal ribosomal entry site; NDA, New Drug Application; UL, unique long.
bI, II, and III indicate phase of clinical trials at time of printing.
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The transcribed RNA molecules, in turn,
serve as the templates that allow the ordering
of the amino acids within the polypeptide chain
of proteins, during the process of translation.
Translation is an appropriate term because the
nucleotide sequence information (language) of
nucleic acids is translated into the amino acid
sequence (language) of protein. The complete
process—DNA makes RNA makes protein—
has been referred to as the central dogma of
molecular biology. A more common term for
the process is gene expression. Thus, the two
stages of gene expression are transcription (the
conversion of DNA to RNA) and translation
(the conversion of RNA to proteins). DNA also
self-replicates to maintain an organism’s
genome. Furthermore, regulation of gene ex-
pression in living organisms involves extensive
recognition and binding to specific nucleic acid
sequences by nucleic acid–binding proteins.
INFORMATIONAL DRUG
DISCOVERY APPROACHES AND
THEIR SUCCESS
Disease states (genetic, oncogenic, or infec-
tive) are typically a result of the production of
abnormal proteins, the end-stage product of
gene expression. Thus, it is not surprising that
drug discovery has historically focused on in-
terfering with the functions of the abnormal
proteins rather than on preventing abnormal
protein formation—treating the disease symp-
toms rather than the cause. In contrast, treat-
ment approaches involving informational chemi-
cals, such as oligonucleotides, attempt to prevent
the formation (gene expression) of abnormal pro-
tein by targeting DNA, RNA, or regulatory pro-
teins that are required for transcription and trans-
lation of the abnormal protein. Having a set of
binding rules (Watson-Crick base-pairing rules)
that allows one to rapidly and precisely select
a molecule to synthesize that will inhibit gene
expression at the DNA or RNA level, and that
offers exquisite specificity for its receptor, is
unique in the history of drug research. Thus,
the employment of informational drugs to com-
plement genomic target validation in modern
drug discovery is revolutionary.
Several discovery approaches are being pur-
sued that employ the encoded information of
modified oligonucleotides as the drug agent
(Tables 4.1.1 and 4.1.2). In the process of tran-
scription, complementary RNA (message RNA
or mRNA) is derived from the sense DNA
strand by Watson-Crick base-pair recognition
and binding. The antisense approach targets the
initial sense complementary RNA strand (pri-
mary transcript) as well as many downstream
sites that are available as RNA is metabolized
in the process of protein production (e.g., splic-
ing, transport, translation; Fig. 4.1.2).
A strict definition of the antisense approach
describes the inhibition of gene expression
through targeting of a predetermined sequence
in an RNA. There are several types of antisense
approaches, which may be differentiated on the
basis of their modes of action (Fig. 4.1.2).
Antisense oligonucleotides primarily operate
by sequence-specific binding to the targeted
RNA. The resultant heteroduplex recruits a
ubiquitous endonuclease, ribonuclease H
(RNase H), to cleave the targeted RNA strand.
Other potential antisense modes of action are
by direct sequence-specific binding of the oli-
gonucleotides to the targeted RNA (or merely
occupying a site on the RNA) such that the
function of essential RNA-binding proteins is
disrupted or that secondary structure required
for gene expression of the RNA is disrupted. A
variety of distinct sites in the intermediary
metabolism of RNA can potentially be targeted
by antisense oligonucleotides with RNase H–
dependent or –independent modes of action
depicted in Figure 4.1.2.
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Figure 4.1.1 Watson-Crick hydrogen-bonding (base-pairing) rules (G to C, A to U or T).
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RNase L, like RNase H, is another cellular
nuclease that cleaves RNA. Its endonucleolytic
cleavage is triggered by binding to (2′-5′)-
linked polyadenylic sequences (Fig. 4.1.3).
Torrence and co-workers have conjugated the
RNase L activating moiety to oligonucleotides
to provide sequence-specific cleavage of tar-
geted RNA (Torrence et al., 1994).
Ribozymes are RNA molecules with cata-
lytic RNA-cleaving activity (Cech, 1986) and
thus represent another type of antisense oli-
gonucleotide. These are typically much longer
RNA molecules that contain both a catalytic
region (which can cleave another RNA seg-
ment) and an adjacent sequence or two se-
quence arms that allow Watson-Crick base-pair
binding to the target. A variety of ribozymes have
been described that differ primarily in their three-
dimensional structures and lengths (reviewed by
Rossi, 1998). The sequence-specific cleavage of
a predetermined RNA target is accomplished
without assistance from any protein.
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Figure 4.1.3 (2′-,5′)-Adenylic oligonucleotides.
Figure 4.1.2 Informational drug-targeting sites. CAP, m7Gppp; W/C, Watson-Crick.
Current Protocols in Nucleic Acid Chemistry
4.1.5
Synthesis of
Modified
Oligonucleotides
and Conjugates
Connection sites
Linkage
Heterocycle
Replace sugar-phosphate
(e.g., amide linkage, PNA)
Pendants
Sugar
Subunits of oligonucleotide to modify
X
A,C,G,T
R
X = O,S,C
O
RO
O
5'
3'
4'
A
2'-Position
A,C,G,T
P
O
O O
O
P O
O
O
O
P S
O
O
O
P NHR
O
O
O
P OR
O
O
O
P BH3
O
O
NH
P OO
O
CH2
P OO
O
S
O
base
O
OMe
base
O
O
OMe
base
O
O
NH2
base
O
F
base
N
P
O
NHR
N
N
NH2
O
Me
N
NN
N
NH2
NH2
N
NN
NH2I
O
O
P S
O
S
O
P CH3
O
O
O
P Se
O
O
N
O
Me
B
HN
O O
S
O base
O
O
NMe2
O base
O
O
NMe2
O base
O
NMe2
O
O base O
base
O
N
NH
O
O
Me
N
N
N
Me
NH2
NH2
N
N
NH
O
O N
N
NH
O
O
O
NH2
O
base
cc.
m.
y.
s. t.
u.
x.w.
Heterocycle modifications
b.a. c. d. e.
f. g. h.
i. j. k. l.
o. q. r.
z.
p.
aa.
v.
Sugar modifications
bb.
ff.
Phosphorous modifications
ee.
n.
Linkage modifications
dd.
N
HN
O
base
O
N
base
O
gg.
Connection modification Sugar-phosphate replacement
Current Protocols in Nucleic Acid Chemistry
4.1.6
Modified
Oligonucleotides
for
Chemotherapeutic 
Applications
Oligonucleotides may also inhibit gene ex-
pression at the DNA level by several antigene
approaches. The most often examined approach
is triple strand formation by oligonucleotides
binding in the major groove of dsDNA via several
Hoogsteen base-pairing rules (Helene, 1993). A
less often examined approach is the use of
oligonucleotides to bind via Watson-Crick
base-pairing rules to a single strand of DNA
available from the formation of a transcription
bubble or locally open-chain site of dsDNA.
Utilizing nucleic acids as decoys to compete
with natural cis-acting sites on dsDNA for es-
sential regulatory proteins is referred to as the
sense approach. In this case, synthetic oligonu-
cleotides (typically dsDNA) are designed to bind
to proteins in a sequence-specific manner.
In another protein-binding approach, ap-
tamers, derived from nucleic acid selection
processes (see Chapter 9), can specifically tar-
get regulatory proteins. Common steps to all
selection methods for nucleic acid–binding
species are: (1) generation of a large pool of
sequence diversity from chemically synthe-
sized DNA pools, (2) transformation of the
pools by enzymatic manipulations such as po-
lymerase chain reaction (PCR) or in vitro tran-
scription, (3) selection of functional shapes,
and (4) amplification. As each RNA sequence
folds into a distinct three-dimensional shape,
and because of the large number of structures
(millions) generated, complementary binding
to a protein target may occur, providing useful
biological properties (reviewed by Bacher and
Ellington, 1998).
Of those drug discovery approaches based
on oligonucleotides, the antisense efforts are
clearly the most advanced, in that twenty three
first-generation phosphorothioate oligonu-
cleotides have entered human clinical trials and
one antisense oligonucleotide has achieved
FDA approval (Table 4.1.4). Much less success
has been accomplished by targeting DNA with
triple-strand-forming oligonucleotides, antis-
ense ribozymes, and RNase L–modified oli-
gonucleotides. From a chemical point of view,
these and other less successful approaches
listed in Tables 4.1.1 and 4.1.2 suffer from not
being amenable to the readily available, first-
generation backbone-modified oligonu-
cleotides such as methylphosphonates, ami-
dates, phosphorothioates, and α oligomers
(Fig. 4.1.4B). Success in these drug discovery
approaches, assuming that the biological ra-
tionale is valid, will require much more inten-
sive chemical efforts.
MODIFICATIONS AND DRUG
PROPERTY ALTERATIONS
A diverse range of modifications at all pos-
sible modification sites of an oligonucleotide
have been reported (reviewed in Cook, 1998a).
Figure 4.1.4A illustrates a dimer of an oligonu-
cleotide depicting possible modifications for
enhancing oligonucleotide drug properties.
These include alterations of heterocycles, car-
bohydrates, linkages (backbones), and connec-
tion and conjugation sites, as well as the com-
plete removal of the sugar-phosphate back-
bone. Most of the positions available in a GC
or AT dimer (∼26 positions for each dimer) that
do not directly interfere with Watson-Crick
base-pair hydrogen bonding have been modi-
fied at one time or another.
The nucleobases or heterocycles of nucleic
acids provide the recognition points for Wat-
son-Crick base pairing and must maintain this
specific interaction in any modification. Thus,
the scope of heterocyclic modifications is quite
limited; this is verified by the fact that only five
or six modified heterocycles have demon-
strated useful oligonucleotide drug properties.
These can be characterized as lipophilic modi-
fications at C5 of pyrimidines and C7 of 7-
deazapurines. Enhanced stacking has been sug-
gested to be the reason for increased binding
Figure 4.1.4 Oligonucleotide modification. (A) Dimer structure showing potential modification
sites. (B) Examples of oligonucleotide modifications: (a) natural phosphate diester; (b) chiral
phosphorothioate; (c) chiral methyl phosphonate; (d) chiral phosphoramidate; (e) chiral phosphate
triester; (f) chiral boranophosphate; (g) chiral phosphoroselenoate; (h) phosphorodithioate; (i)
methylenemethylimino (MMI); (j) 3′-amide; (k) 3′ achiral phosphoramidate; (l) 3′ archiral methylene
phosphonate; (m) thioformacetal; (n) thioethyl ether; (o) 2′-fluoro; (p) 2′-O-methyl; (q) 2′-O-(3-
amino)propyl; (r) 2′-O-(2-methoxy)ethyl; (s) 2′-O-2-(N,N-dimethylaminooxy)ethyl (DMAOE); (t) 2′-
O-2-[2-(N,N-dimethylamino)ethyloxy]ethyl (DMAEOE); (u) 2′-O-N,N-dimethylacetamidyl; (v)
N-morpholinophosphordiamidate; (w) hexose nucleic acid; (x) locked nucleic acid (LNA); (y)
5-propynyluracil-1-yl; (z) 5-methylcytosin-1-yl; (aa) 2-aminoadenin-9-yl; (bb) 7-deaza-7-io-
doadenin-9-yl; (cc) 7-deaza-7-propynyl-2-aminoadenin-9-yl; (dd) phenoxazinyl; (ee) phenoxazinyl-
G-clamp; (ff) α−deoxyribofuranosyl; (gg) peptide nucleic acid (PNA). See Cook (1999).
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affinity with this type of heterocycle modifica-
tion. 2-Aminoadenine represents another
type of modification that provides enhanced
binding affinity. In this case, an additional
hydrogen bond is formed to uracil, providing
significant increases in melting temperature
(Tm). All of these modifications—positioned to
lie in the major or minor groove of the hetero-
duplex—do not affect sugar conformation of
the heteroduplex, and do not provide useful
nuclease resistances, but will support an
RNase H cleavage mechanism.
Modifications in the ribofuranosyl moiety
have provided the most value in the quest to
enhance oligonucleotide drug properties. In
particular, certain 2′-O modifications have
greatly increased binding affinity, increased
nuclease resistance, and altered pharmacoki-
netics, and are potentially less toxic than phos-
phorothioate oligonucleotides (Cook, 1998a).
Preorganization of the sugar into a 3′-endo
pucker conformation is responsible for the in-
creased binding affinity. Unfortunately, no
sugar modification has been reported that is
useful in supporting RNase H cleavage.
Linkage or backbone modifications involve
changes to the nonbridging oxygen atoms, such
as phosphorothioate (P=S), methylphosphon-
ate (Me-P), phosphoramidate (N-P), and others
shown in Figure 4.1.4B, as well as extensive
changes in which the entire four-atom linkage
between sugar moieties is replaced. The most
useful linkage-replacement modification,
MMI (Fig. 4.1.4B), provides greatly enhanced
binding affinities, removes the nuclease-cleav-
able phosphodiester linkage and the chirality
of the phosphorothioate linkage, and allows
adjustments of oligonucleotide lipophilicity
by controlling the negative charge. Of the
linkage changes, only phosphorothioates induce
RNase H cleavage.
Several examples of connection modifica-
tions in oligonucleotides are α-nucleoside link-
age (reverse connection of the heterocycle at
C1′) and (2′-5′)-phosphodiester bonds (in place
of the normal (3′-5′)-phosphodiester bond).
Peptide nucleic acid (PNA) is an example of
the complete removal of the sugar-phosphate
backbone and replacement with a peptide link-
age. In addition to the above modifications,
pendants or conjugation groups can be attached
at many positions in the various subunits to
enhance drug properties.
The antisense concept implies well-defined
structural requirements for the oligonucleotide
ligand that binds to a reasonably characterized
RNA receptor. Although this knowledge of
rather precise binding is of great value and
certainly sets this drug discovery approach
apart from current approaches, additional
modifications are limited to modifications
that do not interfere with Watson-Crick base-
pairing rules.
Modifications of oligonucleotides may be
expected to address essentially every facet of
antisense drug properties. Biophysical and bio-
chemical properties that may be affected by
modifications include binding affinity, base-
pair specificity, nuclease resistance, chemical
stability, lipophilicity, solubility, endonu-
cleolytic cleavage of the RNA of a heterodu-
plex, biological pharmacokinetic properties,
toxicological properties, and pharmacological
properties. Drug properties that will be affected
by altering biophysical and biochemical pa-
rameters include the general areas of pharma-
cokinetics, pharmacodynamics, and toxicol-
ogy. In addition, certain modifications may
represent cost and proprietary patent advan-
tages.
Modifications of short strands of DNA and
RNA for drug purposes should be rationally
directed by drug property deficiencies of the
parent or first-generation oligonucleotides (Ta-
ble 4.1.5). Biological deficiencies are exposed
by pharmacologic, pharmacokinetic, and toxi-
cologic studies of the parent oligonucleotides
at the biophysical, biochemical, in vitro, in
vivo, and clinical levels. In addition, as modi-
fied oligonucleotides move from discovery into
the development pipeline, chemical develop-
ment deficiencies in, for example, larger-scale
synthesis, purification, and analytical proc-
esses will emerge that must be resolved. Finally,
in contemplating research in oligonucleotides,
one should search the patent literature in addi-
tion to examining the traditional scientific lit-
erature, as considerable proprietary positions
of various aspects of the technology have been
achieved. Hopefully, the days of incorporating
nucleosides, novel or known, into oligonu-
cleotides based merely on availability are over.
This nonrational approach was of value in the
beginning of oligonucleotide structure-activity
modifications simply to develop an information
base. Now that more knowledge is available
about what is required to achieve enhanced
properties, current and future oligonucleotide
modifications and studies of their structure-ac-
tivity relationships should be soundly and ra-
tionally based on the need to resolve one or
more of the deficiencies listed in Table 4.1.5,
or to overcome emerging drug process or pro-
duction problems.
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OPTIMIZATION OF BINDING
AFFINITY AND NUCLEASE
RESISTANCE
Oligonucleotide Binding Affinities
Based on the ligand-receptor theory of phar-
macological activity, increasing the affinity of
an oligonucleotide for its RNA target should
increase potency. A relatively simple physico-
chemical experiment is employed to determine
the level of binding and specificity of a modi-
fied oligonucleotide. A complementary oli-
gonucleotide is the simplest target to which an
antisense oligonucleotide can hybridize. Thus,
using length-matched complementary oligonu-
cleotides at stoichiometric concentrations in a
medium that mimics the intracellular environ-
ment as closely as possible (salt, pH, tempera-
ture, concentration), melting curves are em-
ployed to determine how tightly a modified
oligonucleotide binds to its complement. This
involves a spectrophotometric analysis to
measure absorbance versus temperature. The
melting temperature (Tm—the temperature at
which the mixture is half duplex and half sin-
gle-stranded) is determined (Freier et al.,
1992). Oligonucleotide affinity, as measured by
melting curves, increases with the length of the
oligonucleotide-RNA heteroduplex. Thus, 15-
to 25-mers are typically used in antisense ex-
periments rather than shorter oligonucleotides,
which may have Tm values close to or below
physiological temperature and, therefore, may
only form low levels of the required heteroduplex.
A few short oligomers (12-mers or less)
have exhibited interesting biological activity,
and these require modifications leading to high
affinity per nucleotide unit. One interesting
example was the report of potent and selective
inhibition of gene expression by phos-
phorothioates (7- and 8-mers) containing only
5-propynyl-substituted uracil and cytosine
bases (Fig. 4.1.4B; Wagner et al., 1996). Fur-
thermore, several recent studies correlate bind-
ing affinities of a series of 2′-O-modified oli-
gonucleotides with increased in vitro and in
vivo activity (Kawasaki et al., 1993; Morvan et
al., 1993; Monia et al., 1993, 1996; Altmann et
al, 1996a,b,c, 1997). An extensive comparative
listing of binding affinities of 2′-O modifications
was provided by Freier and Altmann (1997).
Oligonucleotide Nuclease Resistance
A number of in vivo pharmacokinetic stud-
ies in several animal species indicate that P=S
oligonucleotides are not as stable as initially
thought (Zhang et al., 1996; Nicklin, 1998).
Although the stability of P=S oligonucleotides
may be sufficient for many drug applications,
greater stability will be helpful in expanding
dosage regimens (longer duration of action
relates to less frequent dosing) and in develop-
ing oral bioavailability. Additionally, less deg-
radation of modified oligomers will minimize
metabolite toxicity. In summary, the prepon-
derance of published antisense biological data
suggests that oligonucleotides with higher
binding affinities and greater stabilities towards
nucleases are important medicinal chemistry
objectives.
STANDARDS ESTABLISHED BY
RECENT SAPR STUDIES
The intense oligonucleotide research per-
formed in the 1990s has provided a remarkable
enhancement of several of the desired antisense
Table 4.1.5 Limitations of First-Generation P=Sa Oligonucleotides
Area Limitation
Pharmacodynamics Low affinity per nucleotide unit:
 low potency
 limited sites to target
Inhibition of RNase H at high concentrations
RNase H mechanism implicated
Pharmacokinetics Limited oral bioavailability
Limited blood-brain barrier penetration
Dose-dependent pharmacokinetics
Toxicologics Release of cytokines
Complement-associated effects on blood pressure?
Clotting effects
Accumulation in kidneys?
aP=S, phosphorothioate.
Current Protocols in Nucleic Acid Chemistry
4.1.9
Synthesis of
Modified
Oligonucleotides
and Conjugates
drug properties. The results achieved with
modified oligonucleotides concerning binding
affinity, base-pair specificity, nuclease resis-
tance, and support of RNase H cleavage of the
targeted RNA is impressive. One should con-
sider the level of binding affinity (as repre-
sented by Tm), nuclease resistance (as repre-
sented by t1/2), and support of an RNase H
mechanism that a new modification should pos-
sess in order to be of interest as a potential drug.
A number of “winners” have been identified
(Fig. 4.1.4B) and discussed in several reviews
(Cook, 1998a,b).
Certain modifications of oligonucleotides
provide an increase in Tm of >1.5°C/modifica-
tion (°C/mod) relative to a P=S oligonucleotide
(∼1.0°C/mod relative to an unmodified P=O
oligonucleotide), and nuclease resistance (t1/2)
of >24 hr with snake venom phosphorodi-
esterase (SVPD; about the same as for P=S). In
view of these values, the author suggests that a
novel modification should exhibit a Tm
>1.5°C/mod compared to its P=S oligonu-
cleotide parent. In evaluation of binding prop-
erties, the modified oligonucleotides should be
hybridized with an RNA complement, as this
is the receptor required for the antisense ap-
proach. A clear correlation between Tm values
derived from hybridization to a DNA comple-
ment or to an RNA has not been established.
Also, correlations of Tm values have not been
established for oligonucleotides having just
one modification (point or pendent modifica-
tion) or several modifications distributed
throughout the sequence, or for those having a
contiguous placement of the modification in the
sequence (Cook, 1991; Lesnik et al., 1993;
Buhr et al., 1996; Matteucci and Krosigk,
1996). Since the application of a modification
will likely require its uniform placement in the
sequence, or at least several contiguous bases
in a row for a gapmer strategy (described below,
Cook, 1993), binding affinity measurements
(Tm) should be taken with these types of modi-
fied oligonucleotides. Furthermore, the modi-
fication must not compromise base-pair speci-
ficity. In this regard, information from a number
of papers suggests that base-pair specificity
actually increases as Tm values are increased.
A specificity that is comparable to base mis-
matches of a P=S phosphorothioate would ap-
pear to be a useful standard.
Nuclease resistance of a novel modification
in a P=O oligonucleotide backbone should at
least be at the level of uniformly modified P=S
oligonucleotides. Given that measurements of
t1/2 values, unlike Tm measurements, are deter-
mined using several procedures (e.g., by incu-
bation with heat-inactivated fetal bovine serum,
purified enzymes such as SVPD, cell or tissue
extracts; or by in vivo dosing followed by
extraction and analysis) under different condi-
tions, the use of P=S oligonucleotide controls
(standards) is necessary. In addition, several
concentrations of nuclease should be employed
to identify and minimize complications leading
to enzyme inhibition (Cummins et al., 1995).
Half-lives of ∼24 hr are often reported for P=S
oligonucleotides in SVPD assays. When the 3′
end of an oligonucleotide is modified to have
sufficient resistance to 3′-exonucleases, en-
donucleolytic cleavage becomes evident. Thus,
modifications should also protect against en-
donucleases. In a gapmer strategy, this is ac-
complished by a phosphorothioate gap, which
will also support an RNase H cleavage mecha-
nism. Nuclease resistance of a modified oli-
gomer, if not provided by the modification, may
in many cases be enabled by employing a P=S
oligonucleotide backbone.
In considering the relative importance of the
nuclease resistance of an antisense oligomer
and its affinity level for its RNA target, recent
biological results suggest that it may be more
important to enhance the stability of an oli-
gonucleotide than its binding affinity (Crooke
et al., 1996a). Modifications that provide high-
binding oligonucleotides with low nuclease re-
sistance have not provided significant biologi-
cal activity, whereas oligonucleotides such as
phosphorothioates have. Although some modi-
fications provide high binding affinities and
high nuclease resistance, they may not exhibit
useful antisense activities because they do not
support an RNase H mechanism. A modifica-
tion that supports an RNase H mode of action
and provides high Tm and nuclease resistance
t1/2 values has not been reported. Thus, an ideal
oligonucleotide modification would provide an
oligomer that hybridizes to target RNA with
high binding affinity and specificity, would be
stable to nucleolytic degradation, and would
allow RNase H cleavage of the RNA target.
This has led to the theory that to optimize the
antisense activity of an oligomer, a combina-
tion of oligonucleotide modifications will be
required (Cook, 1991, 1993).
As noted above, after high-binding, nucle-
ase-resistant 2′-O-modified oligonucleotides
were developed, it was rather disappointing that
oligomers uniformly modified were inactive or
less active than their first-generation parent
phosphorothioates. It is now well known that
uniformly 2′-O-modified oligonucleotides do
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not support RNase H cleavage: the 2′-O-modi-
fied oligonucleotide-RNA heteroduplex pre-
sents a structural conformation that is recog-
nized by the enzyme but is not cleaved (Crooke
et al., 1995; Lima and Crooke, 1997). This lack
of activity has led to the development of a
chimeric strategy (gapmer technology; Cook,
1993; Monia et al., 1993; Yu et al., 1996).
This approach focuses on the design of high-
binding, nuclease-resistant antisense oligonu-
cleotides that are “gapped” with a contiguous
sequence of 2′-deoxyribonucleoside phos-
phorothioates (2′-deoxy/PS)(Fig. 4.1.5). On
hybridization to target RNA, a heteroduplex is
presented that supports RNase H cleavage of
the RNA strand. The stretch of the modified
oligonucleotide-RNA heteroduplex that is rec-
ognized by RNase H may be placed anywhere
within the modified oligonucleotide. The modi-
fications in the flanking regions of the gap
should not only provide nuclease resistance to
exo- and endonucleases, but should also not
compromise binding affinity and base-pair
specificity (Hoke et al., 1991).
Modifications of the phosphorus atom of the
natural phosphodiester linkage (producing
methylphosphonates, phosphorothioates, and
phosphoramidates) destabilize heteroduplexes
−0.7° to −1.5°C per modification (Fig. 4.1.4B;
Agrawal et al., 1990; Dagle et al., 1991; Gui-
nosso et al., 1991). The decreased binding af-
finity of these modified oligonucleotides could
be expected to reduce antisense effectiveness.
In the case of chimeric 2′-O-methyl- or 2′-
fluoro-modified oligonucleotides, an enhance-
ment in the binding affinity of ∼2.0° to 2.3°C
(compared to P=S oligonucleotides) for each
modification is obtained (Sproat et al., 1989;
Guinosso et al., 1991; Miller et al., 1991;
Kawasaki et al., 1993). However, it is now clear
that 2′-O-methyl- and 2′-F-modified DNA are
not sufficiently nuclease resistant to have anti-
sense value as P=O backbones (Sproat et al.,
1989; Morvan et al., 1993; Sproat and Lamond,
1993; Sands et al., 1995; Prasmickaite et al.,
1998). The potential problem in this area can
be circumvented by the use of 2′-O-methyl- or
2′-F-modified phosphorothioates in the flank-
ing regions (doubly modified; Miller et al.,
1991; Kawasaki et al., 1993).
More recent research has focused on 2′-O
modifications such as methoxyethyl (Altmann
et al., 1996a,b,c) and aminopropyl (Griffey et
al., 1996), which not only provide relatively
high binding affinities but also a level of nucle-
ase resistance that allows replacement of thio-
phosphates with natural phosphodiester link-
ages. With a favorable combination of Tm and
t1/2, 2′-O modifications can be employed in the
chimeric strategy (gapmer technology; Fig.
4.1.5), which allows a significant portion of
P=S linkages to be replaced with P=O linkages.
Just how many sulfurs can be replaced depends
on the length of the oligomer and the gap size
or RNase H cleavage site. Typically, a 21-mer
with a 7-nucleotide gap has 65% of the P=S
linkages replaced with P=O linkages. As noted
in the discussion of limitations of P=S oligonu-
cleotides, reduction of the sulfur content in a
P=S oligonucleotide could have important im-
plications in the pharmacokinetic and pharma-
codynamic properties as well as the toxicity
profiles of oligonucleotides (Altmann et al.,
1996a).
A very important aspect of gapmer technol-
ogy is that the gap or RNase H cleavage site
must be protected from endonucleolytic cleav-
age. Phosphodiester linkages and even an alter-
nating P=S/P=O motif do not provide a useful
level of nuclease resistance for biological ac-
tivity (Dagle et al., 1991; Hoke et al., 1991).
The recently reported lack of activity of a
“gapped” 3′-amidate phosphodiester is likely
due to endonuclease degradation (Heidenreich
et al., 1997). Phosphorothioates are the only
useful modification to allow a reasonable com-
bination of binding affinity and nuclease resis-
tance and also support an RNase H mechanism.
Hence, as noted above, most antisense activities
require an RNase H mechanism, which in turn
requires sulfur in the form of thiophosphate
somewhere in the chimeric molecule for nucle-
ase resistance.
An additional issue that should be kept in
mind is the impact that oligonucleotide modi-
fications may have on the cost of future antis-
ense drugs. Again, as a standard, the cost of P=S
oligonucleotides should be considered. The
cost of phosphorothioates has been dramati-
cally reduced due to improvements in the proc-
ess, cost reduction of key reagents, and eco-
5'-
2'-deoxy/PS
FlankFlank Gap
-3'2'-Modifications/PS or PO2'-Modifications/PS or PO
Figure 4.1.5
 Gapmer technology. PO, phosphodiester; PS, phosphorothioate.
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nomics of larger-scale syntheses. As of 1999,
the cost of materials for a 20-mer P=S oligonu-
cleotide was <$300/gram; it is projected to
decline to <$50/gram as larger quantities are
required. The 2′-O-methoxyethyl-modified
oligonucleotides are derived from ribonu-
cleosides and should eventually be substan-
tially less expensive than modified oligonu-
cleotides derived from deoxyribofuranosyl nu-
cleosides. P=S oligonucleotide antisense drugs
are expected to be cost competitive when consid-
ering parenteral (intravenous) treatment three
times/week with a 1 mg/kg dose. Modified
oligonucleotides must be cost effective and will
need to be less expensive to synthesize (e.g.,
shorter), or provide a greater therapeutic index
(increased potency) or other important advan-
tages to offset an increase in the cost of synthesis.
When considering research to modify oli-
gonucleotides, the author believes it is impor-
tant to know the extent to which proprietary
protection of a modification can be obtained.
Important patent positions for many types of
modifications have been established during the
1990s as designing drugs from oligonu-
cleotides has become of interest (Crooke et al,
1996b; Sheffery and Gordon, 1996; Craig et al.,
1997).
GENERAL GUIDELINES FOR
ENHANCING
OLIGONUCLEOTIDE DRUG
PROPERTIES
The excitement roused by the prospect of
using oligonucleotides as drugs stems from the
fact that, unlike other drug discovery ap-
proaches, they are informational materials—
i.e., chemicals having a specific set of rules (the
Watson-Crick base-pairing rules) that clearly
govern their binding to a specific nucleic acid
receptor. In addition, the fact that DNA and
RNA molecules are, compared to proteins,
relatively new molecular targets is of great
interest.
The first test in a SAPR study to determine
whether a modified oligonucleotide is worth
pursuing is whether it maintains its sequence
specificity according to Watson-Crick rules
(Fig. 4.1.6). A newly modified oligonucleotide
that does not possess an acceptable level of
specificity (comparable to that of the P=S oli-
gonucleotide) is an immediate failure. The next
step is to determine how tightly the modified
oligonucleotide binds to its target nucleic acid.
As noted, the binding affinity of a modified
oligomer is a physicochemical property, deter-
mined by measuring the oligomer’s sequence-
specific interaction with its length-matched
RNA complement. The hybridization or melt-
ing process is performed under a rather standard
set of conditions designed to mimic an intracel-
lular environment (Freier et al., 1992). Because
this calculation is done under artificial condi-
tions, it may not accurately represent the bind-
ing of an oligomer to a native RNA inside a cell.
The next essential property of an oligonu-
cleotide is sufficient resistance to degradation
by exo- and endonucleolytic plasma and tissue
nucleases (Fig. 4.1.6). Nuclease resistance is
determined in various assays, such as incubat-
ing the oligonucleotide in heat-inactivated fetal
bovine serum, cellular extracts, or purified exo-
nucleases or endonucleases (also see Standards
Established by Recent SAPR Studies). These
results are also likely to differ from the stability
of an oligomer in vivo. However, these Tm and
t1/2 assays do allow SAPR studies to proceed,
and thus provide reasonable methods to com-
pare various oligonucleotide modifications at
an early developmental stage. This is quite
different from traditional drug discovery ap-
proaches.
CONJUGATED
OLIGONUCLEOTIDES
The sugar, heterocycle, and backbone (link-
age) subunit modifications as depicted in Fig-
ure 4.1.4A are core modifications that greatly
enhance binding affinities and nuclease resis-
tance of antisense oligonucleotides. To enhance
other antisense drug properties of an optimized,
core-modified oligonucleotide, a variety of
molecules (pendants) have been attached (con-
jugated) in a point-modification motif (i.e.,
only one pendant in an antisense oligonu-
cleotide). Pendant modifications have primar-
ily been directed to enhancing oligonucleotide
uptake. Other potential applications of pendants
include increased solubility, lipophilicity, and
means to attach synthetic cleaving agents,  inter-
calators (for improvements in binding affinity),
and cross-linking and alkylating groups (see UNITS
4.2 & 4.3). Several reviews have discussed oli-
gonucleotide pendants (Cook, 1991, 1993; Ma-
noharan, 1993; De Mesmaeker et al., 1995).
PERSPECTIVE
One P=S oligonucleotide drug (Vitravene)
is available as of 1999, and others will follow
in the next several years. However, to continu-
ally improve this novel and exciting drug class,
and to overcome certain limitations, structural
changes are required. In the 1990s a diverse
range of modifications, at all possible modifi-
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cation sites of an oligonucleotide (Fig. 4.1.4A),
has been reported. This application of tradi-
tional medicinal chemistry (SAPR studies) to
drug discovery in antisense oligonucleotides,
and in oligonucleotides in general, has an-
swered many important questions. For exam-
ple, as a result of this rather intense effort,
modifications are now known that stabilize
oligonucleotides towards nucleolytic degrada-
tion (e.g., 2′-O-methoxyethyl and 2′-O-amino-
propyl), that greatly enhance binding affinities
while maintaining base-pair specificity (e.g.,
2′-O-methoxyethyl), and that support endonu-
cleolytic cleavage by RNase H (e.g., 5-
propynyl pyrimidines). Although these are bio-
chemical and biophysical properties, a large
volume of cellular and animal studies support
the notion that enhancing these properties cor-
relates with enhanced antisense biological ac-
tivity in vivo. Unfortunately, a single modifica-
tion that provides high binding affinity nucle-
ase-resistance and support of an RNase H
mechanism is not available. A modification of
this nature is of current interest in the antisense
approach.
It is also known that changing the structure
of phosphorothioate oligonucleotides provides
an opportunity to alter their pharmacokinetic
profile. Structural changes that remove sulfur
(as thiophosphate) and/or change lipophilicity
(e.g., by 2′-O modifications) have resulted in
more favorable toxicity profiles (Altmann et al.,
1996a). Although research has revealed these
important antisense properties (and there may
be many more to learn about), and has shown
how to control them, it has not yet determined
the optimum values at which these modifica-
tions should be aimed. In addition, the lack of
•  Synthesis of novel or known nucleosides  
•  Synthesis of novel amidites with appropriate protection
 
•  Development of oligomerization protocol process/analysis
•  Synthesis of  modified oligonucleotide in standard sequences
•  Synthesis of length-matched complementry RNA sequences and single base 
    mismatches and appropriate control sequences
•  Obtain binding affinities (change in Tm in degrees/modification) of matched and 
    mismatched modified oligonucleotide
Sequence-specificity and binding affinity of 
modification improved compared to standards
Sequence-specificity or binding 
affinity of modification below standards
Abandon modification
•  Prepare appropriate modified oligonucleotides for
    nuclease studies
•  Determine relative nuclease resistance
Nuclease-resistance of modified 
oligonucleotides less than standards
Modified oligonucleotide possess greater 
nuclease-resistance than standards
Consider additional modifications, e.g.,  
combination of modifications, for enhancing 
nuclease resistance while maintaining 
binding affinity
Examine modified oligonucleotide
with target sequence (tissue culture 
reduction of message and/or protein)
Advanced pharmacology, 
pharmacokinetics and toxicology 
studies
Figure 4.1.6 General pathway for structure-activity/property relationship studies.
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antisense oligonucleotides that are orally avail-
able and/or penetrate the blood-brain barrier
represents the most important deficiency of
antisense oligonucleotides. Recent reports of
antisense P=S oligonucleotides doubly modi-
fied at the 3′ and 5′ ends with 2′-O-methyl or
2′-O-methoxyethyl—to provide a high level of
nuclease resistance—have provided encouraging
results suggesting that these pharmacokinetic de-
ficiencies will soon be solved by appropriate
chemical modifications (Agrawal et al., 1995).
One should be aware of the level of accom-
plishments achieved in oligonucleotide medici-
nal chemistry research in the course of the
1990s. Binding affinities, nuclease resistance,
support of RNase H, and cost of synthesis have
been discussed in this unit, and they should be
considered (as standards) before initiating or
continuing oligonucleotide modification re-
search. In addition, understanding the proprie-
tary patent positions that have been established
is an important research consideration. The
author believes that, at this stage of oligonu-
cleotide medicinal chemistry, it is highly un-
likely that a single modification will be discov-
ered that will significantly affect all of the
important drug properties described above. The
types of modified oligonucleotides currently
being pursued (going beyond P=S oligonu-
cleotides) possess a combination of modifica-
tions, and this trend will certainly continue as
pendants will be conjugated to oligonu-
cleotides with optimized core subunits to obtain
a “completely” optimized oligonucleotide drug.
The current “winners,” or the first modifi-
cations most likely to be incorporated into an-
tisense oligonucleotides that will undergo clini-
cal t r ials,  are the RNA mimics 2′-O-
methoxyethyl and 2′-O-aminopropyl, and the
backbone modification MMI (Fig. 4.1.4B).
These will likely be utilized in a gapmer strat-
egy. However, efforts to prepare uniform modi-
fications, such as RNA mimics (2′-O-modifi-
cations), MMI, and PNA are of considerable
interest, in that reliance on RNase H for a mode
of action would not be required. In addition to
these modifications that act either by direct
binding (RNase H independent) or via RNase
H, the author believes that subunit pendant
modifications (such as cholesterol conjugates
and folic acid conjugates) will become increas-
ingly important for optimizing multiply modi-
fied oligonucleotides.
LITERATURE CITED
Agrawal, S., Mayrand, S.H., Zamecnik, P.C., and
Pederson, T. 1990. Site-specific excision from
RNA by RNase H and mixed-phosphate-back-
bone oligodeoxynucleotides. Proc. Natl. Acad.
Sci. U.S.A. 87:1401-1405.
Agrawal, S., Zhang, X., Lu, Z., Zhao, H., Tamburin,
J.M., Yan, J., Cai, H., Diasio, R.B., Habus, I.,
Jiang, Z., Iyer, R.P., Yu, D., and Zhang, R. 1995.
Absorption, tissue distribution and in vivo stabil-
ity in rats of a hybrid antisense oligonucleotide
following oral administration. Biochem. Phar-
macol. 50:571-576.
Alderfer, J.L., Loomis, R.E., Soni, S.D., Sharma,
M., Bernacki, R., and Hughes, R. Jr. 1985. Ha-
logenated nucleic acids: Biochemical and bio-
logical properties of fluorinated polynu-
cleotides. Polymeric Mater. Med. 32:125-138.
Altman, S. 1989. Ribonuclease P: An enzyme with
a catalytic RNA subunit. Adv. Enzymol. 62:1-36.
Altmann, K.H., Dean, N.M., Fabbro, D., Freier,
S.M., Geiger, T., Häner, R., Hüsken, D., Martin,
P., Monia, B.P., Müller, M., Natt, F., Nicklin, P.,
Phillips, J., Pieles, U., Sasmor, H., and Moser,
H.E. 1996a. Second generation of antisense oli-
gonucleotides: From nuclease resistance to bio-
logical efficacy in animals. Chimia 50:168-176.
Altmann, K.H., Kesselring, R., and Pieles, U. 1996b.
6′-Carbon-substituted carbocyclic analogs of 2′-
deoxyribonucleosides: Synthesis and effect on
DNA/RNA duplex stabili ty.  Tetrahedron
52:12699-12722.
Altmann, K.H., Fabbrot, D., Dean, N.M., Geiger, T.,
Monia, B.P., Muller, M., and Nicklin, P. 1996c.
Second-generation antisense oligonucleotides:
Structure-activity/relationships and the design of
improved signal-transduction inhibitors. Bio-
chem. Soc. Trans. 24:630-637.
Altmann, K.H., Martin, P., Dean, N.M., and Monia,
B.P. 1997. Second generation antisense oligonu-
cleotides—inhibition of pkc-α and c-raf kinase
expression by chimeric oligonucleotides incor-
porating 6′-substituted carbocyclic nucleosides
and 2′-O-ethylene glycol substituted ribonu-
cleosides. Nucleosides Nucleotides 16:917.
Bacher, J.M. and Ellington, A.D. 1998. Nucleic acid
selection as a tool for drug discovery. Drug Dis-
covery Today 3:265.
Bardos, T.J. and Ho, Y.K. 1978. Chemical and En-
zymatic Methods in the Synthesis of Modified
Polynucleotides. In Symposium on the Chemis-
try and Biology of Nucleosides and Nucleotides
(R.E. Harmon, R.K. Robins, and L. Townsend,
eds.) pp. 55-68. Academic Press, Orlando, Fla.
Belikova, A.M., Zarytova, V.F., and Grivneva, N.I.
1967. Synthesis of ribonucleosides and diri-
bonucleoside phosphates containing 2-chlo-
roethylamine and nitrogen mustard residues. Tet-
rahedron Lett. 7:3557-3562.
Buhr, C.A., Wagner, R.W., Grant, D., and Froehler,
B.C. 1996. Oligodeoxynucleotides containing
C-7 propyne analogs of 7-deaza-2′-deoxy-
guanosine and 7-deaza-2′-deoxyadenosine.
Nucl. Acids Res. 24:2974-2980.
Current Protocols in Nucleic Acid Chemistry
4.1.14
Modified
Oligonucleotides
for
Chemotherapeutic 
Applications
Cech, T.R. 1986. RNA as an enzyme. Sci. Am.
255:64-75.
Chandra, P. and Bardos, T.J. 1972. Inhibition of
DNA polymerases from RNA tumor viruses by
novel template analogs. Partially thiolated poly-
cytidylic acid. Res. Commun. Chem. Pathol.
Pharmacol. 4:615-622.
Cohen, J.S. 1991. Informational drugs: A new con-
cept in pharmacology. Antisense Res. Dev.
1:191-193.
Connell, C., Fung, S., Heiner, C., Bridgham, J.
Chakarian, V., Heron, E., Jones, R., Menchen, S.,
Mordan, W., Raff, M., Recknor, M., Smith, L.,
Springer, J., Woo, S., and Hunkapiller, M. 1987.
Automated DNA sequence analysis. BioTech-
niques 5:342.
Cook, P.D. 1991. Medicinal chemistry of antisense
oligonucleotides—future opportunities. Anti-
Cancer Drug Design 6:585-607.
Cook, P.D. 1993. Medicinal chemistry strategies for
antisense research. In Antisense Research and
Applications (S.T. Crooke and B. Lebleu, eds.)
pp. 149-187. CRC Press, Boca Raton, Fla.
Cook, P.D. 1998a. Antisense medicinal chemistry.
In Handbook of Experimental Pharmacology
(S.T. Crooke, ed.) pp. 51-101. Springer-Verlag,
Heidelberg, Germany.
Cook, P.D. 1998b. Second generation antisense oli-
gonucleotides: 2′-Modifications. Annu. Rep.
Med. Chem. 33:313.
Cook, P.D. 1999. Making drugs out of oligonu-
cleotides: A brief review and perspective. Nu-
cleosides Nucleotides 18:1141-1162.
Craig, A., Vanstone, D., and Sudhir, A. 1997. Patent
strategies in the antisense oligonucleotide based
therapeutic approach. Expert Opin. Ther. 7:1175.
Crooke, S.T., Lemonidis, K.M., Neilson, L., Griffey,
R., Lesnik, E.A., and Monia, B.P. 1995. Kinetic
characteristics of Escherichia coli RNase H1:
Cleavage of various antisense oligonucleotide-
RNA duplexes. J. Biochem. 312:599-608.
Crooke, S.T., Graham, M.J., Zuckerman, J.E.,
Brooks, D., Conklin, B.S., Cummins, L.L., Greig,
M.J., Guinosso, C.J., Kornbrust, D., Manoharan,
M., Sasmor, H.M., Schleich, T., Tivel, K.L., and
Griffey, R.H. 1996a. Pharmacokinetic properties
of several novel oligonucleotide analogs in mice.
J. Pharmacol. Exp. Ther. 277:923-937.
Crooke, S.T., Bernstein, L.S., and Boswell, H.
1996b. Progress in the development and patent-
ing of antisense drug discovery technology. Ex-
pert Opin. Ther. 6:855-870.
Cummins, L.L., Owens, S.R., Risen, L.M., Lesnik,
E.A., Freier, S.M, McGee, D., Guinosso, C.J.,
and Cook, P.D. 1995. Characterization of fully
2′-modified oligoribonucleotide hetero- and ho-
moduplex hybridization and nuclease sensitivity.
Nucl. Acids Res. 23:2019-2024.
Dagle, J.M., Andracki, M.E., DeVine, R.J., and Wal-
der, J.A. 1991. Physical properties of oligonu-
cleotides containing phosphoramidate-modified
internucleoside linkages. Nucl. Acids Res.
19:1805-1810.
De Clercq, E., Eckstein, F., and Merigan, T.C. 1969.
Interferon induction increased through chemical
modification of a synthetic polyribonucleotide.
Science 165:1137-1139.
DeMesmaeker, A., Haner, R., Martin, P., and
Moser, H.E. 1995. Antisense oligonucleotides.
Acc. Chem. Res. 28:366-374.
Ellington, A.D. and Szostak, J.W. 1990. In vitro
selection of RNA molecules that bind specific
ligands. Nature 346:818-822.
Freier, S.M. and Altmann, K.-H. 1997. The ups
and downs of nucleic acid duplex stability:
Structure-stability studies on chemically-modi-
fied DNA: RNA duplexes. Nucl. Acids Res.
25:4429-4443.
Freier, S.M., Lima, W.F., Sanghvi, Y.S., Vickers,
T., Zounes, M., Cook, P.D., and Ecker, D.J. 1992.
Thermodynamics of antisense oligonucleotide
hybridization. In Gene Regulation: Biology of
Antisense RNA and DNA, Vol. 1 (Series: Mo-
lecular Cellular Biology) (R.P. Erickson and
J.G. Izant, eds.) pp. 95-107. Raven Press, New
York.
Griffey, R.H., Monia, B.P., Cummins, L.L., Freier,
S., Greig, M.J., Guinosso, C.J., Lesnik, E.,
Manalili, S.M., Mohan, V., Owens, S., Ross,
B.R., Sasmor, H., Wancewicz, E., Weiler, K.,
Wheeler, P.D., and Cook, P.D. 1996. 2′-O-ami-
nopropyl ribonucleotides: A zwitterionic modi-
fication that enhances the exonuclease resis-
tance and biological activity of antisense oli-
gonucleotides. J. Med. Chem. 39:5100-5109.
Guinosso, C.J., Hoke, G.D., Freier, S.M., Martin,
J.F., Ecker, D.J., Mirabelli, C.K., Crooke, S.T.,
and Cook, P.D. 1991. Synthesis and biophysical
and biological evaluation of 2′-modified anti-
sense oliogonucleotides. Nucleosides Nucleo-
tides 10:259-262.
Heidenreich, O., Gryaznov, S., and Nerenberg, M.
1997. RNase H-independent antisense activity of
oligonucleotide N3′-P5′ phosphorothioates.
Nucl. Acids Res. 25:776.
Helene, C. 1993. Control of gene expression by
triple-helix-forming oligonucleotides: The an-
tigene strategy. In Antisense Research and Ap-
plications (S.T. Crooke and B. Lebleu, eds.) pp.
375-385. CRC Press, Boca Raton, Fla.
Hoke, G.D., Draper, K., Freier, S.M., Gonzalez, C.,
Driver, V.B., and Zounes, M.C. 1991. Effects of
phosphorothioate capping on antisense oligonu-
cleotide stability, hybridization and antiviral ef-
ficacy versus herpes simplex virus infection.
Nucl. Acids Res. 19:5743.
Kawasaki, A.M., Casper, M.D., Freier, S.M., Les-
nik, E.A., Zounes, M.C., Cummins, L.L., Gon-
zalez, C., and Cook P.D. 1993. Uniformly
mod i f ied  2′-deoxy-2′- f luo ro  phos-
phorothioate oligonucleotides as nuclease-re-
sistant antisense compounds with high affinity
and specificity for RNA targets. J. Med. Chem.
36:831-841.
Current Protocols in Nucleic Acid Chemistry
4.1.15
Synthesis of
Modified
Oligonucleotides
and Conjugates
LeDoan, T., Perrouault, L., Praseuth, D., Habhoub,
N., Decout, J.L., Thuong, N.T., Lhomme, J., and
Helene, C. 1987. Sequence-specific recognition,
photocrosslinking and cleavage of the DNA dou-
ble helix by an oligo-[α]-thymidylate covalently
linked to an azidoproflavine derivative. Nucl.
Acids Res. 15:7749.
Lesnik, EA., Guinosso, C.J., Kawasaki, A.M., Sas-
mor, H., Zounes, M., Cummins, L.L., Ecker,
D.J., Cook, P.D., and Freier, S.M. 1993. Oligode-
oxynucleotides containing 2′-O-modified
adenosine: Synthesis and effects on stability of
DNA:RNA duplexes. Biochemistry 32:7832-
7838.
Lima, W.F. and Crooke, S.T. 1997. Binding affinity
and specificity of Escherichia coli RNase H1:
Impact on the kinetics of catalysis of antisense
oligonucleotide-RNA hybrids. Biochemistry
36:390-398.
Manoharan, M. 1993. Designer antisense oligonu-
cleotides: Conjugation chemistry and function-
ality placement. In Antisense Research and Ap-
plications (S.T. Crooke and B. Lebleu, eds.) pp.
303-349. CRC Press, Boca Raton, Fla.
Matteucci, M.D. and von Krosigk, U. 1996. Hy-
bridization properties of oligonucleotides bear-
ing a tricyclic 2′-deoxycytidine analog based on
a carbazole ring system. Tetrahedron Lett.
37:5057-5060.
Miller, P.S., Bhan, P., Cushman, C.D., Kean, J.M.,
and Levis, J.T. 1991. Antisense oligonucleotide
methylphosphonates and their derivatives. Nu-
cleosides Nucleotides 10:37-46.
Monia, B.P., Lesnik, E.A., Gonzalez, C., Lima, W.F.,
McGee, D., Guinosso, C.J., Kawasaki, A.M.,
Cook, P.D., and Freier, S.M. 1993. Evaluation of
2′-modified oligonucleotides containing 2′-de-
oxy gaps as antisense inhibitors of gene expres-
sion. J. Biol. Chem. 268:14514-14522.
Monia, B.P., Johnston, J.F., Sasmor, H., and Cum-
mins, L.L. 1996. Nuclease resistance and anti-
sense activity of modified oligonucleotides tar-
geted to Ha-ras. J. Biol. Chem. 271:14533-
14540.
Morishita, R., Givvons, G.H., Kaneda, Y., and Dzau,
V.J. 1995. Pharmacokinetics of antisense oli-
godeoxynucleotides (cyclin B1 and cdc2 kinase)
in the vessel wall in vivo: Enhanced therapeutic
utility for restenosis by HVJ-liposome delivery.
Gene 149:13-19.
Morvan, F., Porumb, H., Degols, G., Lefebvre, I.,
Pompon, A., Sproat, S., Rayner, B., Malvy, C.,
Lebleu, B., and Imbach, J.-L. 1993. Comparative
evaluation of seven oligonucleotide analogues as
potential antisense agents. J. Med. Chem.
36:280-287.
Moser, H.E. and Dervan, P.B. 1987. Sequence-spe-
cific cleavage of double helical DNA by triple
helix formation. Science 238:645-650.
Nicklin, P. 1998. Pharmacokinetics properties of
phosphorothioates in animals. In Handbook of
Experimental Pharmacology (S.T. Crooke, ed.)
pp. 141-168. Springer-Verlag, Heidelberg, Ger-
many.
Prasmickaite, L., Hogset, A., Maelandsmo, G.,
Berg, K., Goodchild, J., Perkins, T., Fodstad, O.,
and Hovig, E. 1998. Intracellular metabolism of
a 2′-O-methyl-stabilized ribozyme after uptake
by DOTAP transfection or as free ribozyme. A
study by capillary electrophoresis. Nucl. Acids
Res. 26:4241-4248.
Rossi, J.J. 1998. Therapeutic ribozymes: Principles,
applications, and problems. In Applied Antis-
ense Oligonucleotide Technology (C.A. Stein
and A.M. Krieg, eds.) pp. 511-525. Wiley-Liss,
New York.
Sands, H., Gorey-Feret, L.J., Ho, S.P., Bao, Y.,
Cocuzza, A.J., Chidester, D., and Hobbs, F.W.
1995. Biodistribution and metabolism of inter-
nally 3H-labeled oligonucleotides. II. 3′,5′-
Blocked oligonucleotides. Therapeutics 47:636-
646.
Sheffery, M. and Gordon, C.L. 1996. Leadership
positions in antisense patents (company report).
Mehta and Isaly Equity Research, New York.
Sproat, B.S. and Lamond, A.I. 1993. 2′-O-Alkyloli-
goribonucleotides. In Antisense Research and
Applications (S.T. Crooke and B. Lebleu, eds.)
pp. 351-362. CRC Press, Boca Raton, Fla.
Sproat, B.S., Lamond, A.I., Beijer, B., and Neuner,
U. 1989. Highly efficient chemical synthesis of
2′-O-methyloligoribonucleotides and tetrabio-
tinylated derivatives; novel probes that are resis-
tant to degradation by RNA or DNA specific
nucleases. Nucl. Acids Res. 17:3373-3386.
Stephenson, M.L. and Zamecnik, P.C. 1978. Inhibi-
tion of Rous sarcoma viral RNA translation by a
specific oligodeoxyribonucleotide. Proc. Natl.
Acad. Sci. U.S.A. 75:285-288.
Summerton, J. 1979. Intracellular inactivation of
specific nucleotide sequences: A general ap-
proach to the treatment of viral diseases and
virally-mediated cancers. J. Ther. Biol. 78:77-99.
Torrence, P.F., Xiao, W., Li, G., Lesnik, K., Kham-
nei, S., Maran, A., Maitra, R., Dong, B., and
Silverman, R.H. 1994. 2′,5′-Oligoadenylate an-
tisense chimeras for targeted ablation of RNA in
carbohydrate modifications. In Antisense Re-
search (Y.S. Sanghvi and P.D. Cook, eds.) pp.
118-132. American Chemical Society, Washing-
ton, D.C.
Ts’o, P.O., Miller, P.S., Aurelian, L., Murakami, A.,
Agris, C., Blake, K.R., Lin, S.B., Lee, B.L., and
Smith, C.C. 1987. An approach to chemotherapy
based on base sequence information and nucleic
acid chemistry. Matagen (masking tape for gene
expression). Ann. N.Y. Acad. Sci. 507:220-241.
Tuerk, C. and Gold, L. 1990. Systematic evolution
of ligands by exponential enrichment: RNA li-
gands to bacteriophage T4 DNA polymerase.
Science 249:505-510.
Wagner, R.W., Matteucci, M.D., Grant, D., Huang,
T., and Froehler, B.C. 1996. Potent and selective
inhibition of gene expression by an antisense
heptanucleotide. Nat. Biotechnol. 14:840-844.
Current Protocols in Nucleic Acid Chemistry
4.1.16
Modified
Oligonucleotides
for
Chemotherapeutic 
Applications
Yu, D., Iyer, R.P., Shaw, D.R., Lisziewicz, J., Li, Y.,
Jiang, Z., Roskey, A., and Agrawal, S. 1996.
Hybrid oligonucleotides: Synthesis, biophysical
properties, stability studies, and biological activ-
ity. Bioorg. Med. Chem. Lett. 4:1685-1692.
Zamecnik, P.C. and Stephenson, M.L. 1978. Inhibi-
tion of Rous sarcoma virus replication and cell
transformation by a specific oligodeoxynu-
cleotide. Proc. Natl. Acad. Sci. U.S.A. 75:280-
284.
Zhang, R., Iyer, R.P., Yu, D., Tan, W., Zhang, X., Lu,
Z., Zhao, H., and Agrawal, S. 1996. Pharmaco-
kinetics and tissue disposition of a chimeric oli-
godeoxynucleoside phosphorothioate in rats af-
ter intravenous administration. J. Pharmacol.
Exper. Ther. 278:971-979.
Zon, G. 1993. History of antisense drug discovery.
In Antisense Research and Applications (S.T.
Crooke and B. Lebleu, eds.) pp. 1-5. CRC Press,
Boca Raton, Fla.
Contributed by P. Dan Cook
Isis Pharmaceuticals
Carlsbad, California
Current Protocols in Nucleic Acid Chemistry
4.1.17
Synthesis of
Modified
Oligonucleotides
and Conjugates
